QualityDipStocks / Health Care · Pharmaceuticals
Travere Therapeutics TVTX
Outside our quality screen, so we don’t track its dips. It’s 27% below its 52-week high.
Outside our quality screen, 16% under its Market Value. No fair value estimate for now: there isn’t enough data.
Worth knowing
- Down 28% from its 52-week high while revenue grew 49%
From the data on this page, as of the last close. How we pick these
- Fair value est.
- n/a
- Market Value
- $58.64price −16%
- Off 52-wk high
- −27%
- Risk vs market
- Above marketbeta 1.35
5 bullish · 5 bearish See why
Repriced or dip?
Repricing: business changed
The price is 27% below its 52-week high (Aug 27), but the business held up: revenue +10.1%, shares outstanding fewer shares, each owns more.
Some numbers held up (revenue +10.1%, shares outstanding fewer shares, each owns more), others slipped (revenue growth rate −27.7 pts, operating margin −13.7 pts). The price is 27% below its 52-week high.
The price is 27% below its 52-week high, and the business changed too: revenue growth rate −27.7 pts, operating margin −13.7 pts.
Within 10% of its 52-week high, so there is no dip to judge yet.
The evidence 6 numbers, high vs now
- Revenue, last 12 months$591M → $651M (+10.1%)held up
- Revenue growth rate+77.1% → +49.4% a year (−27.7 pts)changed
- Operating margin−6.8% → −20.5% (−13.7 pts)changed
- Shares outstanding−0.1% (fewer shares, each owns more)held up
- Stock vs its sector (Health Care)stock −27%, sector median 0% since Aug 27changed
- Price fall vs business numbersprice −27%, revenue/EPS/FCF median +10% (shown, not scored)
Business numbers as reported at the high (12 months to Jun 30, 2026) vs the latest filing (12 months to Sep 30, 2026). Each measure is scored from −1 (business changed) to +1 (business intact) and weighted: revenue, earnings per share, free cash flow, operating margin, revenue growth rate, share count, net cash and the move vs its sector. 60 or more reads as a dip, 40 or less as a repricing. Analyst estimates are not in our data, so they are not used. How to read it
Data-based read, not advice.
Valuation
What we estimate it's worth, and how it ranks on value vs every stock we cover.
Fair value estimate
No estimate for TVTX: Capital spending isn't tagged for the latest period in SEC XBRL data. We’d rather show nothing than a made-up number.
Risk vs market
How risk vs market is measured
One year of daily returns (Oct 31 to Nov 2, 252 sessions). Beta = how much TVTX moved for each 1% move in the S&P 500 (SPY); 1.0 moves with the market. Volatility is the yearly standard deviation of daily returns. Past behavior, not a forecast.
Swings more than the market, and its own price swings are 5.1× the S&P 500’s.
- Beta vs S&P 500
- 1.35
- Volatility
- 65% vs 13% SPY
- Correlation SPY
- 0.27
- Correlation QQQ
- 0.22
How it ranks
Where TVTX stands vs every one of the 1,996 stocks we cover that has the number. Longer bar = better.
Top quarter on 1 of 3 measures
- Dividends + buybacks yield0% · cash paid out or used to retire shares, vs market capLowest 1%of 1,836
- Revenue growth, last 12 months+49% · vs the 12 months beforeTop 7%of 1,814
- Operating margin−21% · of sales kept as operating profitLowest 4%of 1,288
From SEC filings and our fair value estimate model. A ranking, not advice.
Valuation details
MV $58.64
Fundamentals
The business itself: sales, profits, cash and debt, from SEC filings.
Bull vs bear
Rule-based from the data on this page, strongest first. Not advice.
Top bullish points 5 of 5
GrowthSales grew 49% to $651M over the last 12 months vs the 12 months before (SEC filings).
ProfitabilityOperating margin widened to −12.8% in FY2025 from −267.2% in FY2023 (SEC filings).
GrowthSales compounded 65% a year from FY2022 to FY2025.
Cash returnsShare count down 7.8% in a year.
ValuationTrades 16.0% below its Market Value of $58.64, the average price paid since the Aug 4 filing.
Top bearish points 5 of 5
Balance sheetOperating income covers interest only -15.0× over the last 12 months.
ProfitabilityLost $122M over the last 12 months (net income, SEC filings).
ProfitabilityLoses money at the operating line: −21% operating margin over the last 12 months.
ValuationPrice / book of 203.7×, above the 5.2× median for the 217 Health Care companies we cover.
QualityDoesn’t pass our quality screen: no positive free cash flow; ROE under 12% and ROIC under 10%; net debt 5.6× EBITDA (limit 3×).
All fundamentals
Sales +49%
Valuation
- P/E
- n/aloss over the last 12 months
- Price / FCF
- n/anot reported in its SEC filings
- FCF yield
- n/anot reported in its SEC filings
- EV / EBITDA
- n/aD&A or debt not tagged in SEC data
- Price / sales
- 7.07×
- Price / book
- 203.68×
- Market cap
- $4.6Blisted
- Enterprise value
- n/anot reported in its SEC filings
Growth
- Revenue, 12 months
- $651M
- Sales growth, 12 months
- +49.4%vs the 12 months before
- Sales growth, 3 yrs
- +64.9%/yrfrom FY2022
- Diluted EPS, 12 months
- −$1.30
- EPS growth, last FY
- n/afewer than two years of diluted EPS
- Net income, 12 months
- −$122M
- Net income growth
- n/anot reported in its SEC filings
Profitability
- Gross margin
- 98.5%
- Operating margin
- −20.5%
- Net margin
- −18.7%
- FCF margin
- n/anot reported in its SEC filings
- Return on equity
- n/an/m: very small or negative equity
- Return on invested capital
- n/aoperating income, debt, equity or cash not tagged
Balance sheet
- Cash & short-term inv.
- $303M
- Total debt
- n/anot reported in its SEC filings
- Net cash
- n/acash or debt not tagged in SEC data
- Debt / equity
- n/adebt or equity not tagged in SEC data
- Interest coverage
- -15.0×operating income / interest
Cash flow & returns
- Free cash flow, 12 months
- n/anot reported in its SEC filings
- FCF growth, 12 months
- n/anot reported in its SEC filings
- Dividend yield
- 0%
- Payout ratio
- n/anot reported in its SEC filings
- Buybacks, 12 months
- n/anot reported in its SEC filings
- Share count, 1 year
- −7.8%diluted shares vs a year ago
- Stock-based comp
- $73M
Trailing 12 months to Sep 30, 2026; balance sheet at Sep 30, 2026. From Travere Therapeutics’s SEC filings. Sparklines show up to six fiscal years. n/a means we don’t hold that number, with the reason. How each is computed.
The business
FCF $-0.0B · Sales +48%
- Free cash flow, 12 months−$0.0B
- Free-cash-flow yield−0.4%
- Free-cash-flow margin−3%
- Gross margin59%
- Operating margin2%
- Return on invested capital7%
- Return on equity−236%
- Sales growth (latest quarter vs year-ago quarter)+48%
- Net debt / EBITDA5.6×
Chart & levels
Where the price is vs its key levels and trends.
Key levels
Every level vs today’s $49.26
- 52-wk lowlowest close, 1 year$26.79−45.6%
- PriceMon Nov 2 close$49.26you are here
- Market Valueavg paid since Aug 4$58.64+19.0%
- 52-wk highhighest close, 1 year$67.52+37.1%
Momentum & 52-week range
RSI 32 · 5 days −1.4%
Signals
Reversal signal setups, the public ledger and the next earnings date.
Setup & signals
No setup armed
No setup armed, so there’s no trigger or stop to track yet. Reversal signal rules only run on companies that pass our quality screen.
TVTX is outside our quality screen
One text when a published rule fires on one of the 332 quality companies we track: the ticker, the price, the stop and a link to the numbers. Nothing else.
Voices & buzz
Who is talking about it, and how it compares with peers.
Who’s talking about it
Notable investors, executives, analysts and public figures on Travere Therapeutics in the last 48 hours. Headlines as published, each linked. Their words, not ours.
No notable mentions in the last 48 hours. Checked Nov 3, 1:01 PM ET.
Compare with peers
Closest in size in Pharmaceuticals
Information only, not investment advice. Fair value estimates and talking points are rule-based model output from public data and can be wrong; stop levels are reference points, not orders. How every number is computed.